Please login to the form below

Not currently logged in
Email:
Password:

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare)

September 2018: Independent professional body guideline

Asthma (update)

September 2018: NICE Quality Standard

Depression in adults (update)

September 2018: NICE Quality Standard

Eating disorders

September 2018: NICE Quality Standard

Ovarian cancer (refresh)

September 2018: SIGN guidance

Renal replacement therapy

October 2018: NICE Clinical Guideline

Decision making and mental capacity

October 2018: NICE Social Care Guidance

Foetal alcohol spectrum disorder (update)

October 2018: SIGN guidance

Abdominal aortic aneurysm: diagnosis and management

November 2018: NICE Clinical Guideline

Contraceptive choices for women who are obese/overweight

November 2018: Independent professional body guideline

Visit the Guidelines website

NICE approves BioMarin’s Brineura after initial setback

NICE approves BioMarin’s Brineura after initial setback 12 Sep 2019
The positive recommendation of Brineura was agreed by NICE’s Highly Specialised Technology committee. ... NICE seems to have jumped the gun, approving the therapy before the review of the new data.

Novartis’ CAR-T Kymriah scores SMC approval

Novartis’ CAR-T Kymriah scores SMC approval 10 Sep 2019
treatments. The medicine went through the SMC’s Patient and Clinician Engagement (PACE) process, which considers medicines that treat end of life and rare conditions. ... Following this recommendation, the cost-effectiveness watchdog then recommended

NICE backs NHS use of Novartis’ gene therapy Luxturna

NICE backs NHS use of Novartis’ gene therapy Luxturna 4 Sep 2019
The Scottish Medicines Consortium (SMC) is due to deliver its verdict on the gene therapy in December. ... We are delighted with today’s decision by NICE to recommend voretigene neparvovec for use in patients with vision loss due to a genetic mutation

Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate

Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate 23 Aug 2019
Judgement arrives ahead of European approval. GW Pharma’s Epidyolex for two types of severe treatment-resistant epilepsy has been given a preliminary rejection by England’s NICE – but the cost ... We remain hopeful that NICE will recommend

NICE’s long-serving chief exec Sir Andrew Dillon to step down

NICE’s long-serving chief exec Sir Andrew Dillon to step down 22 Aug 2019
Sir Andrew has led NICE with a laser focus on establishing how the latest medicines can benefit patients and the NHS.". ... The board of NICE says it will make arrangements to advertise the chief executive’s post during the autumn.

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Infographics